Franklin Resources’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Franklin Resources’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-29,696	Closed	-$127K	–	2398
2022 Q3	$127K	Buy	29,696 +310	+1%	+$1.31K	﹤0.01%	2071
2022 Q2	$114K	Sell	29,386 -14,232	-33%	-$40.5K	﹤0.01%	2128
2022 Q1	$208K	Hold	43,618	–	–	﹤0.01%	2145
2021 Q4	$159K	Hold	43,618	–	–	﹤0.01%	2275
2021 Q3	$350K	Buy	+43,618	New	+$430K	﹤0.01%	2033
2014 Q4	–	Sell	-6,254	Closed	-$9.38M	–	1609
2014 Q3	$9.38M	Sell	6,254 -2,574	-29%	-$3.73M	﹤0.01%	1051
2014 Q2	$12.1M	Hold	8,828	–	–	0.01%	1021
2014 Q1	$12.3M	Buy	+8,828	New	+$10.3M	0.01%	987

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Franklin Resources's VIRX Position: Q4 2022 in Review

Franklin Resources sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2022, closing a stake of 29,696 shares — an estimated $127K sold.

Franklin Resources first reported a position in VIRX in Q1 2014 and held it in 8 quarters. The position peaked at $12.3M in Q1 2014. 56 funds tracked by Wall St. Rank hold VIRX as of Q4 2022.

Franklin Resources reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Franklin Resources sold 29,696 Viracta Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $127K.
Franklin Resources first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2014 and held it in 8 quarters.
Franklin Resources's Viracta Therapeutics, Inc. Common Stock position peaked at $12.3M in Q1 2014.
56 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Franklin Resources's 13F filing for Q4 2022, filed 10 Feb 2023.